FLJ46266_4833427G06Rik Inhibitors
Staurosporine, LY294002, Wortmannin, and Rapamycin represent a group of inhibitors that directly modulate the signaling pathways which can regulate the activity of FLJ46266_4833427G06Rik. Staurosporine acts as a potent inhibitor of protein kinase C, among other kinases, thereby potentially diminishing the phosphorylation of target proteins that may be essential for FLJ46266_4833427G06Rik's activity. LY294002 and Wortmannin are both inhibitors of phosphoinositide 3-kinases (PI3K). LY294002 functions by competitively inhibiting the ATP binding site of PI3K, leading to a blockade of the PI3K/Akt pathway, while Wortmannin forms a covalent bond with a lysine residue in the catalytic domain of PI3K, irreversibly inhibiting its activity. This inhibition of PI3K can prevent the formation of PIP3 and subsequent activation of Akt, thereby disrupting the signaling required for FLJ46266_4833427G06Rik function. Rapamycin specifically inhibits the mammalian target of rapamycin (mTOR), a central regulator of cell growth and proliferation; its inhibition leads to a disruption in mTOR signaling pathways that could be crucial for the regulation of FLJ46266_4833427G06Rik.
PD98059, U0126, SB203580, SP600125, PP2, Bortezomib, Sorafenib, and Imatinib comprise another set of inhibitors that impact the activity of FLJ46266_4833427G06Rik through various intracellular mechanisms. PD98059 and U0126 target MEK1/2, key components of the MAPK/ERK pathway, with PD98059 acting as a selective inhibitor and U0126 functioning as a non-competitive inhibitor. Both lead to a reduction in ERK-mediated cellular functions which can influence FLJ46266_4833427G06Rik activity. SB203580 selectively inhibits p38 MAPK, affecting cellular responses to stress and cytokines that could regulate FLJ46266_4833427G06Rik. SP600125 inhibits JNK, thereby potentially reducing transcriptional activity of genes that could be essential for FLJ46266_4833427G06Rik's function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is an alkaloid that inhibits a broad spectrum of protein kinases. It inhibits protein kinase C, which could be essential for FLJ46266_4833427G06Rik activation if this protein is dependent on phosphorylation by this kinase. Inhibition of protein kinase C by staurosporine would result in decreased phosphorylation and activation of FLJ46266_4833427G06Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). If FLJ46266_4833427G06Rik requires PI3K signaling for activation, LY294002 inhibition of PI3K would reduce the production of PIP3, leading to decreased Akt phosphorylation and subsequent reduction in FLJ46266_4833427G06Rik activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a steroidal metabolite that acts as an irreversible inhibitor of PI3K. By blocking PI3K, it prevents Akt activation. If FLJ46266_4833427G06Rik is downstream of Akt signaling, wortmannin would lead to reduced functional activity of FLJ46266_4833427G06Rik by preventing necessary phosphorylation events. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. If FLJ46266_4833427G06Rik is part of the mTOR signaling pathway, its activity could be downregulated by rapamycin via inhibition of mTOR complex 1 (mTORC1), which is crucial for cell growth and proliferation signaling that might involve FLJ46266_4833427G06Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. If FLJ46266_4833427G06Rik's function is regulated via the MAPK pathway, PD98059 would inhibit MEK, suppressing ERK activation and reducing the activity of FLJ46266_4833427G06Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK inhibitor that prevents the activation of MAPK/ERK. This would lead to diminished ERK-mediated signaling processes that may be essential for the regulation or function of FLJ46266_4833427G06Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK by SB203580 would lead to decreased regulation of stress responses and cytokine production that could influence the functional activity of FLJ46266_4833427G06Rik if it's involved in these pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). Inhibition of JNK can prevent the transcriptional activation of genes that are necessary for the function of FLJ46266_4833427G06Rik, leading to reduced activity of the protein. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 would reduce tyrosine phosphorylation that might be required for FLJ46266_4833427G06Rik function or interaction with other cellular proteins. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. By inhibiting the proteasome, bortezomib can lead to the accumulation of regulatory proteins that may control the degradation or stability of FLJ46266_4833427G06Rik, thereby potentially reducing its functional activity. | ||||||